Answers are grounded in this paper and cite their sources.
Findings reveal Bifidobacterium adolescentis reduces weight loss in mice with DSS-induced colitis, indicating its therapeutic potential for inflammatory bowel disease.
Description Inflammatory bowel disease (IBD) is a chronic condition with rising prevalence and no known cure. The gut microbiota play a critical role in maintaining intestinal homeostasis and modulating the immune system, particularly through IL-10-producing regulatory T (Treg) and B (Breg) cells, which suppress inflammation. This study aimed to identify symbiotic microbes for managing gut inflammation by isolating Lactobacillus and Bifidobacterium strains from healthy human feces. Among the isolates, Bifidobacterium adolescentis (Bifi-94) significantly enhanced IL-10 production in vitro. Oral administration of Bifi-94 to mice for two weeks reduced weight loss and alleviated DSS-induced colon inflammation. In wild-type B6 mice, Bifi-94 increased IL-10 levels in colon homogenates without altering Treg cell subsets. CD19?CD11b? B1 cells in peritoneal exudate cells (PECs) were identified as the primary IL-10 source following Bifi-94 exposure. IL-10 secretion was triggered by live, heat-killed, and formalin-fixed Bifi-94. Peptidoglycan from Bifi-94 was identified as a key driver of IL-10 production in CD19?CD11b? B1 cells. Comparative analysis showed Bifi-94 expressed higher levels of peptidoglycan synthesis proteins, such as MurE, MurT, Alr, and UppP, than the reference strain KCTC3216. These findings suggest Bifi-94-derived peptidoglycan enhances IL-10 production, promotes Breg cell activity, and mitigates gut inflammation, highlighting its therapeutic potential for IBD.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: